Zila’s OraTest Oral Cancer Screen Lags At CDER; ZTC Clears Premarket Hurdle
This article was originally published in The Gray Sheet
Executive Summary
Zila Medical's strategy of seeking an adjunctive claim for its ZTC tolonium chloride compound enabled a relatively quick device review, CEO Douglas Burkett said in a Feb. 7 conference call
You may also be interested in...
Zila Gains Direct Sales Force For Oral Diagnostic Combo Product
Zila's acquisition of Professional Dental Technologies provides a direct U.S. sales force to market its ViziLite Plus oral tissue "abnormality test" and clinical trial-phase OraTest oral cancer diagnostic
Zila Gains Direct Sales Force For Oral Diagnostic Combo Product
Zila's acquisition of Professional Dental Technologies provides a direct U.S. sales force to market its ViziLite Plus oral tissue "abnormality test" and clinical trial-phase OraTest oral cancer diagnostic
Zila's OraTest Rinse Needs Additional Study, FDA Advisory Committee Says
Zila should conduct another trial of its OraTest oral cancer diagnostic, FDA's Oncology Drugs Advisory Committee determined Jan. 13.